Seeking Alpha
Profile| Send Message| ()  

When constructing different stock screens, I like to focus on certain aspects such as P/E ratio, EPS trends, and quarterly growth, and in this case, I'm going to focus on four pharmaceutical companies expected to grow by at least 23% during the second quarter.

For this screen, I wanted to focus on four companies that met three specific criteria. First, each of these companies had to have a market cap of under $400 million. Second, each of these companies must be projected to grow at least 23% during the second quarter. Last but not least, each of these companies must be currently trading under $6.50/share, but no less than $4/share. In my opinion, the lower a stock trades, the riskier it is.

Symbol

Price

Mkt. Cap

Q2 PG

FY PG

52 Wk High

52 Wk Low

ONTY

4.33

247.36 M

85.70%

50.00%

3.35

11.59

SGMO

5.17

271.87 M

30.00%

25.40%

2.36

6.30

CADX

4.49

384.07 M

23.30%

35.90%

2.56

9.15

FOLD

6.07

281.50 M

32.40%

10.90%

2.10

7.64

Oncothyreon, Inc., which trades in a 52-week range of $3.35/share (52-week low) to $11.59/share (52-week high), has a market cap of $247.36 million and is expected to grow 85.70% during the second quarter which is 8.57 times that of the S&P 500. For the second quarter, ONTY is expected to post a -$0.13/share loss, however if the company can post a narrower than expected loss, growth may exceed the current estimate of 32.40% for the quarter. Investors should note that the company did surpass analysts' estimates for the first quarter by 18.8%.

Potential investors looking to establish a position in ONTY should do so with a small- to medium-sized position and pay very close attention to the company's drugs Stimuvax and PX-866. Both drugs have made significant progress since their inception and continue to progress in a forward manner based on their current status (Stimuvax is currently engaged in two separate Phase III clinical trials and PX-866 just announced interim results with regard to Phase II clinical trials).

Sangamo, Inc., which trades in a 52-week range of $2.36/share (52-week low) to $6.30/share (52-week high), has a market cap of $247.36 million and is expected to grow 30.00% during the second quarter which is 3.00 times that of the S&P 500. For the second quarter, SGMO is expected to post a -$0.14/share loss, however if the company can post a narrower than expected loss, growth may exceed the current estimate of 30.00% for the quarter. Investors should note that the company did surpass analysts' estimates for the first quarter by 12.5%.

Potential investors looking to establish a position in SGMO should do so with a small- to medium-sized position and pay very close attention to the company's developmental progress with regard to ZFPs (Zinc Finger Proteins) which can be used as either ZFP transcription factors (ZFP-TFs) or ZFP nucleases (ZFNs). Both ZFPs have made significant progress since their inception and continue to progress in a forward manner based on their current status (SB-728-T is currently engaged in separate Phase II and Phase I/II clinical trials and SB-313xTZ that is currently engaged in Phase I clinical trials).

Cadance Pharmaceuticals, Inc., which trades in a 52-week range of $2.56/share (52-week low) to $9.15/share (52-week high), has a market cap of $384.07 million and is expected to grow 23.30% during the second quarter which is 2.23 times that of the S&P 500. For the second quarter, CADX is expected to post a -$0.23/share loss, however if the company can post a narrower than expected loss, growth may exceed the current estimate of 23.30% for the quarter.

Potential investors looking to establish a position in CADX should do so with a small- to medium-sized position and pay very close attention to the company's drug OFIRMEV, which is a proprietary intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children. The main catalyst with regard to OFIRMEV is sales, and those sales could surpass $11.2 million during the second quarter.

Amicus Therapeutics, Inc., which trades in a 52-week range of $2.10/share (52-week low) to $7.64/share (52-week high), has a market cap of $281.50 million and is expected to grow 30.00% during the second quarter which is 3.24 times that of the S&P 500. For the second quarter, SGMO is expected to post a -$0.25/share loss, however if the company can post a narrower than expected loss, growth may exceed the current estimate of 30.00% for the quarter.

Potential investors looking to establish a position in CADX should do so with a small- to medium-sized position and pay very close attention to the company's developments of Enzyme Replacement Therapies (ERT), especially when applied to those patients with Pompe disease.

Source: 4 Stocks Expected To Grow At Least 23% That Should Be Considered At Current Levels